EPODIN represents an important patient community in Europe suffering of life-threatening neurological conditions, and which rely on adequate access to lifesaving plasma-derived medicinal products (PDMPs). 1.EPODIN welcomes the proposed EU Pharma Regulation with its focus on tackling and preventing medicines shortages.
EPO
European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN)
NGO · France · EU Transparency Register 551594935772-82
4
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #390 by legislative files engaged, a count of participation, not a measure of influence.
3
declared lobbying FTE
self-declared
–
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2019
in the register since
Declares membership of
- Member of EURORDIS
- Member of the European network EURO-NMD
- Member of EFNA
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Registered as
- European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN)
- Head office
- LE POULIGUEN, France
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track European in PolicySpeak: request access →
Work at European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN)? so we know who speaks for it.
Their record over time
European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN) filed 4 positions between 8 Sept 2022 and 5 Aug 2026, across 3 of the 665 legislative files tracked here, attaching a full position paper 1 time.
2022 · 1 filed2023 · 2 filed2026 · 1 filed
What they argued
EPODIN represents an important patient community in Europe suffering of severely life-threatening neurological medical conditions. EPODIN welcomes the Commission proposal for a separate EU Pharma Directive and strongly supports the overall objective to harmonise the rules governing pharmaceuticals to ensure better access to medicines for EU patients.
EPODIN European Patient Organisation for Dysimmune Inflammatory Neuropathies welcomes the European Commission's proposal for an EU Biotech Act as a timely and ambitious initiative to strengthen Europe's biotechnology ecosystem, enhance its global competitiveness and ensure that scientific excellence translates into faster development, availability and equitable access to innovative medicines for all European…
EPODIN POSITION AND PROPOSALS (see full version attached) EPODIN thanks the European Commission for all its work. In particular, EPODIN strongly supports the balanced approach of the European Commission. The complexity of the topic, and the multiplicity of stakeholders make the SOHO legislation something complex to work on.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN) next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 85.
Is this your organization?
Everything on this page comes from European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN)’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.